DucemBio to Invest 33.56 Billion Won in Radiopharmaceutical CDMO Plant

DucemBio will invest 33.5 billion won to build a contract development and manufacturing (CDMO) plant for radiopharmaceutical therapies and an R&D center.

DucemBio disclosed that its board of directors approved a 33.5612 billion won investment in new facilities at a meeting on the 4th.

The investment is intended to build an RPT (radiopharmaceutical therapy)-focused CDMO plant and R&D center. The amount represents 68.2% of the company’s equity capital (49.23997 billion won).

The investment period runs from the 7th through Dec. 31, 2032. The new investment site is in the Advanced Industrial Complex in Sinjeong-dong, Jeongeup.

The investment amount excludes the cost of purchasing the land. The company said the amount and period may change depending on future permitting schedules, construction progress and changes in the business environment.

Equity capital is based on the financial statements for the end of 2025, prepared in accordance with Korean International Financial Reporting Standards (K-IFRS). Authority to determine and execute the details has been delegated to the CEO.